Entera Bio

ENTXNasdaq Israel Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$141.463 M

$2.87 +1.77%

Close of 7 Aug 2026

Revenue

$42.0K

#3630 by revenue

Earnings

-$11.4M

Loss-making

Shares outstanding

173,141,831

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#108Innate PharmaIPHA$162.3M
#109HumacyteHUMA$159.5M
#110Entera BioENTX$141.5M
#111enGene TherapeuticsENGN$120.6M
#112Black Diamond TherapeuticsBDTX$112.0M

Where these numbers come from

Share counts and financials for Entera Bio are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.